# US 2024/0238303 A1 · Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0238303 A1
- Document ID: US20240238303A1
- Status: Published application
- Kind: A1
- Application number: 18/289,288
- Filed: 2022-05-04
- Published: 2024-07-18
- Earliest claimed: 2021-05-04
- Assignees: Enalare Therapeutics Inc.
- Applicants: Enalare Therapeutics Inc.
- Inventors: Robert B. RAFFA; Joseph V. PERGOLIZZI
- Web page: https://patentgrep.com/patent/US20240238303A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- C07D 251/54: Three nitrogen atoms
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D 239/50: Three nitrogen atoms
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are methods of treating a disease or condition modulated by large-conductance potassium channels, the methods including administering, to a patient in need thereof, an effective amount of a large-conductance potassium channel modulating compound. Exemplary disease or conditions that may be treated include, without limitations, protection against ischemia and hypoxia at multiple points throughout the body, as well as respiration stimulation in the presence of such conditions (both local and systemic). Also described herein are pharmaceutical compositions for use in the methods of treatment of a disease or condition modulated by large-conductance potassium channels, and methods of preparing such pharmaceutical compositions.

## Claims

### Claim 1

A method of treating a disease or condition modulated by large-conductance potassium channels comprising administering, to a patient in need thereof, an effective amount of a large-conductance potassium channel modulating compound selected from compound(s) of Formula (I):
wherein:
R1 and R2 are independently H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, heteroaryl or substituted heteroaryl; or R1 and R2 combine as to form a biradical selected from the group consisting of 3-hydroxy-pentane-1,5-diyl, 6-hydroxy-cycloheptane-1,4-diyl, propane-1,3-diyl, butane-1,4-diyl and pentane-1,5-diyl;
R3 is H, alkyl, substituted alkyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —NR1R2, —C(O)OR1, acyl, or aryl;
R4 is H, alkyl, or substituted alkyl;
R5 is H, alkyl, propargylic, substituted propargylic, homopropargylic, substituted homopropargylic, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —OR1, —NR1R2, —C(O)OR1, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic; or R3 and R5 combine as to form a biradical selected from the group consisting of 3,6,9-trioxa-undecane-1,11-diyl and 3,6-dioxa-octane-1,8-diyl;
R6 is H, alkyl, substituted alkyl or alkenyl;
X is a bond, O or NR4; and,
Y is N, CR6 or C; wherein:
if Y is N or CR6, then bond b1 is nil and: (i) Z is H, bond b2 is a single bond, and A is CH; or, (ii) Z is nil, bond b2 is nil, and A is a single bond; and,
if Y is C, then bond b1 is a single bond, and: (i) Z is CH2, bond b2 is a single bond, and A is CH; or, (ii) Z is CH, bond b2 is a double bond, and A is C;
or a salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one substituent selected from the group consisting of R1, R2, R3 and R1 as described with respect to Formula (I), is alkynyl or substituted alkynyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease or condition is neurological disorder.

### Claim 4 (depends on 3)

The method of claim 3, wherein the neurological disorder is epilepsy, paroxysmal dyskinesia, or schizophrenia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease or disorder is a cardiac disorder.

### Claim 6 (depends on 4)

The method of claim 4, wherein the cardiac disorder is cardiac ischemia or cardiac hypoxia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease or disorder is a cerebral disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cerebral disorder is cerebral ischemia or cerebral hypoxia.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is an agonist.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound is an antagonist.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound modulates at one or both of the pore gate or the voltage sensing domain of the large-conductance potassium channel.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound modulates at one or both of the RCK1 or the RCK2 of the large-conductance potassium channel.

### Claim 13 (depends on 1)

The method of claim 1, wherein the large-conductance potassium channel is located at one or both of a pre-synaptic or post-synaptic site.

### Claim 14 (depends on 1)

The method of claim 1, wherein the large-conductance potassium channel is located at one or both of cardiovascular smooth muscle and cardiac fibroblasts.

### Claim 15 (depends on 1)

The method of claim 1, wherein the disease or condition is associated with one or more of airway surface liquid and mucociliary clearance.

### Claim 16 (depends on 1)

The method of claim 1, wherein the disease or condition requires organ protection.

### Claim 17 (depends on 16)

The method of claim 16, wherein the organ protection is one or both of cerebro and cardio.

### Claim 18 (depends on 1)

The method of claim 1, wherein the administration route is selected from oral, intravenous, nasal, inhalational, topical, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratrachael, otic, intraocular, or intrathecal route.

### Claim 19

A pharmaceutical composition comprising an effective amount of a large-conductance potassium channel modulating compound selected from Formula (I):
wherein:
R1 and R2 are independently H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, heteroaryl or substituted heteroaryl; or R1 and R2 combine as to form a biradical selected from the group consisting of 3-hydroxy-pentane-1,5-diyl, 6-hydroxy-cycloheptane-1,4-diyl, propane-1,3-diyl, butane-1,4-diyl and pentane-1,5-diyl;
R3 is H, alkyl, substituted alkyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —NR1R2, —C(O)OR1, acyl, or aryl;
R4 is H, alkyl, or substituted alkyl;
R5 is H, alkyl, propargylic, substituted propargylic, homopropargylic, substituted homopropargylic, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, —OR1, —NR1R2, —C(O)OR1, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic; or R3 and R5 combine as to form a biradical selected from the group consisting of 3,6,9-trioxa-undecane-1,11-diyl and 3,6-dioxa-octane-1,8-diyl;
R6 is H, alkyl, substituted alkyl or alkenyl;
X is a bond, O or NR4; and,
Y is N, CR6 or C; wherein:
if Y is N or CR6, then bond b1 is nil and: (i) Z is H, bond b2 is a single bond, and A is CH; or, (ii) Z is nil, bond b2 is nil, and A is a single bond; and,
if Y is C, then bond b1 is a single bond, and: (i) Z is CH2, bond b2 is a single bond, and A is CH;
or, (ii) Z is CH, bond b2 is a double bond, and A is C;
or a salt thereof, and
a pharmaceutically acceptable excipient.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein at least one substituent selected from the group consisting of R1, R2, R3 and R5 as described with respect to Formula (I), is alkynyl or substituted alkynyl.

### Claim 21 (depends on 19)

A method of preparing the pharmaceutical composition of claim 19, the method comprising, combining an effective amount of the large-conductance potassium channel modulating compound selected from Formula (I) with a pharmaceutically acceptable excipient.
